Stock Evaluator: Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics, Inc. LRMR

$2.99 -0.01 -0.33%
November 17, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,376,889
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Commentary & Analysis


Financial Summary

Share Statistics LRMR Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $314.9 $208.2 34%
Shares Out (Mil) 104.7 55.4 62%
Institutional Ownership 97.5% 92.9% 74%
Float (Mil) 57.0 40.7 49%
Beta 0.70 1.00 40%
Avg Daily Volume (000s) 1,519 570 75%
Price Change
(52-week)
(11.4%) 40.7% 42%
Growth LRMR Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) (31.3%) (10.3%) 13%
EPS (5yr) 8.7% 15.5% 45
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (34.0%) (15.7%) 16%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 6 4 8
Current EPS ($0.333) ($1.180) ($0.905)
Month Ago EPS ($0.385) ($1.351) ($1.060)
# Rev Up 0 0 0
# Rev Down 1 2 2
Three Months Ago EPS ($0.385) ($1.351) ($1.060)
Year/Year Chg 12.1% (48.0%) (85.8%)
Financials LRMR Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $39 na
Net Income (TTM) (Mil) ($156) ($44) 8%
EPS (TTM) ($1.622) ($1.400) 16%
Operating Cash Flow (TTM) (Mil) ($158) ($34) 4%
Net Cash Flow (TTM) (Mil) ($13) $-0 31%
Long-Term Debt (Q1) (Mil) $3 $4 22%
Enterprise Value (Q1) (Mil) $192 $138 27%
Valuation LRMR Industry
Median
Percentile
(All Stocks)
P/B 3.09 1.96 70%
P/E na 17.7 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.8 na
Ratios LRMR Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.9% na
Net Margin na (50.8%) na
ROA (95.2%) (47.4%) 6%
ROE (129.8%) (51.6%) 7%
Liabilities to Assets 27.8% 29.7% 19%
F-Score 2 3 7%

Larimar Therapeutics, Inc. did not pass any screens on 11/17/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors